# Midline catheter use for cancer patients receiving 5-FU chemotherapy: prospective study of safety and outcomes

## TL;DR

Using midline catheters for 5-FU chemotherapy in cancer patients prevents phlebitis and improves satisfaction for patients and healthcare providers.

## Contribution

Demonstrates midline catheters as a safe alternative for 5-FU infusion, reducing phlebitis and healthcare burdens.

## Key findings

- No phlebitis occurred in 59 patients using midline catheters for 5-FU infusion.
- High satisfaction rates were reported by over 90% of patients and 80% of healthcare providers.
- Midline catheter insertion success rate was 98.3% with minimal complications.

## Abstract

Peripheral intravenous 5-fluorouracil (5-FU) administration often causes phlebitis and necessitates catheter replacement, imposing burdens on both patients and healthcare providers. Insertion of a midline catheter (MLC) into the upper arm with tip positioned in the axillary vein may reduce the incidence of phlebitis. This study evaluated the safety and effectiveness of MLC use for continuous 5-FU infusion in cancer patients.

This prospective study included patients with cancer requiring at least 4 days of continuous 5-FU infusion. The primary endpoint was the incidence of phlebitis. Secondary endpoints were the success rate of MLC insertion, complications, and patient-reported outcomes.

Of the 61 patients enrolled, 59 were included in the analysis. The median age was 68 years, and primary cancer types were esophageal (51%) and head and neck (46%). The median MLC indwelling duration was 5.5 days (2-28 days). No phlebitis was observed (0%, 95% CI: 0–6.2), achieving the primary endpoint. The insertion success rate was 98.3%, with complications in 6.8%. Over 90% of patients and 80% of healthcare providers reported high satisfaction levels.

MLC insertion is a safe and effective approach for continuous 5-FU infusion, eliminating phlebitis, potentially improving patients’ quality of life, and reducing healthcare providers’ workloads. (ClinicalTrials.gov Identifier: jRCTs042230058).